NEW YORK — GenomOncology said Thursday that it has signed an agreement allowing it to offer its customers access to curated genomic data within Genomenon's Mastermind platform.
Mastermind includes thousands of curated genes and a catalog of gene-disease relationships, all aligned with American College of Medical Genetics and Genomics guidelines and assessed according to ClinGen standards.
Under the terms of the deal, GenomOncology will incorporate the Mastermind data into its Precision Oncology Platform, an end-to-end clinical informatics tool for cancer. The Cleveland-based company said that the additional data will help its customers streamline the classification process for germline variants and improve genomic reporting for clinicians.
Financial and other terms were not disclosed.
"This partnership will enable us to offer a more comprehensive and efficient approach to germline variant classification, ensuring that clinicians have the insights they need to make informed decisions when diagnosing and treating heritable diseases," GenomOncology Chief Commercial Officer Garreth Hippe said in a statement.
In September, GenomOncology struck a deal to incorporate its clinical genomic reporting software with Precipio's test for myeloid neoplasms.
Earlier this week, Ann Arbor, Michigan-based Genomenon expanded its ongoing partnership with Sophia Genetics to integrate the Mastermind Genome Search Engine into the Sophia artificial intelligence platform and Alamut Suite for genomic analysis.